ProBio celebrated the opening of its flagship Cell and Gene Therapy Center of Excellence at the Princeton West Innovation Campus in Hopewell.
The 128,000 sq ft GMP facility is purpose-built for manufacturing high-quality plasmid DNA and viral vectors, including adeno-associated virus (AAV) and lentiviral vector (LVV) platforms.
The celebration included an open house event featuring a guided site tour, ribbon-cutting ceremony, and a keynote address by Donavon Decker, the first person in the world to receive gene therapy for any form of muscular dystrophy in 1999.
The ribbon-cutting ceremony featured remarks from Debbie Hart, CEO of BioNJ; Courtney Peters–Manning, mayor of Hopewell Township; John Coelho of the New Jersey Economic Development Authority (NJEDA); Michael Vreeland, site head of ProBio Hopewell; Allen Guo, CEO of ProBio; and Frank Zhang, founder of GenScript and Chairman of Legend Biotech.
John Coelho of NJEDA emphasized the strategic significance of the opening: “The opening of ProBio, a state-of-the-art fully integrated end-to-end Contract Development and Manufacturing Organization, will be a significant enhancement to the cell and gene biologics development and biomanufacturing ecosystem, anchoring New Jersey as a leader in the field. The potential to support production for global clinical trial registrations and close proximity to leading precision medical centers will enable faster access of breakthrough medicines to patients.”
The Hopewell site is equipped to support clinical-stage development, process-development and scale-up for cell and gene therapy programs.
“This is not just a new facility. It is a beacon of hope for patients waiting for cures,” Allen Guo, CEO of ProBio said. “Opening the Hopewell center is a milestone in ProBio’s global expansion and underscores our mission to support biopharma innovators with high-quality, responsive manufacturing solutions.”
Bringing over 110 high-skilled jobs to New Jersey, ProBio’s Hopewell facility continues to expand its capabilities. GMP AAV manufacturing is set to launch by Q3 2025, with GMP LVV services to follow in Q1 2026—enabling support for a broader range of therapeutic candidates from early proof-of-concept through clinical readiness, all within one integrated site.
